The available evidence does not verify that a family shared a mother's final written message before Alzheimer's took her ability to write. The closest traceable account says a Reddit user's mother found a note written by her father before the disease impaired his communication. That distinction matters because the writer's identity and the note's "final" status remain unconfirmed. Alzheimer's disease is an irreversible, progressive brain disorder that damages memory, thinking, communication, and eventually the ability to perform simple tasks.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the original post actually establishes
- How Alzheimer's can affect writing
- Does losing the ability to write prove Alzheimer's?
- Can treatment restore a lost writing ability?
- What families can do with preserved writing
What the original post actually establishes
The December 2021 Reddit post describes a note found by the poster's mother and written by her father. It does not establish that a mother wrote the note or that it was her last written message. The post may still capture something emotionally real: a family preserved a written connection from before communication became harder.
However, a social-media caption cannot confirm the writer's diagnosis, disease stage, prognosis, or exact writing history. Calling the note "final" adds a claim the source does not support. A careful description would call it a preserved note written before Alzheimer's impaired the person's communication.
How Alzheimer's can affect writing
Writing requires several abilities working together, including language, memory, attention, and the control needed to form letters or use a device. Alzheimer's can disrupt these abilities as brain changes progress, but each person's symptoms and timeline differ. The National Institute on Aging lists difficulty with language, reading, writing, or numbers among possible symptoms of moderate Alzheimer's.
In severe disease, a person may become unable to communicate and fully dependent on care, according to the NIA guide to Alzheimer's signs. A writing change might appear as trouble finding words, organizing a sentence, spelling familiar terms, or handling numbers. One example cannot show which underlying ability has changed, and not everyone with Alzheimer's loses writing skills in the same way.
Does losing the ability to write prove Alzheimer's?
No. A change in writing is meaningful personal evidence, but it is not a diagnosis. Other dementias and health conditions can produce similar cognitive symptoms, and Alzheimer's requires a clinical assessment.
Families should look for patterns rather than treating one note, misspelling, or unfinished sentence as proof. Useful observations to bring to an evaluation include: The goal is not to test or confront the person at home. It is to give a clinician concrete information that may help distinguish an isolated mistake from a broader decline.
- When the change began and whether it is getting worse
- Specific examples involving writing, reading, speech, memory, or numbers
- Whether the difficulty affects familiar daily tasks
- Any preserved notes or messages that show a change over time
Can treatment restore a lost writing ability?
Current evidence does not show that Alzheimer's treatment can restore writing after that ability has been lost. The strongest evidence for newer anti-amyloid drugs concerns slowing decline in selected people at an early stage, not reversing established disability. The FDA traditionally approved Leqembi, or lecanemab, in July 2023 after a confirmatory trial. It was studied for people with confirmed amyloid pathology and either mild cognitive impairment or mild Alzheimer's dementia, as described in the FDA's Leqembi approval record.
The FDA approved Kisunla, or donanemab, in July 2024. In a 76-week trial involving 1,736 participants with confirmed amyloid and mild cognitive impairment or mild dementia, it reduced decline compared with placebo by 2.92 points on the trial's combined cognitive and daily-function measure, according to the FDA's Kisunla notice. These drugs also have important limits. Kisunla carries a boxed warning for amyloid-related imaging abnormalities, which can involve brain swelling or bleeding; rare cases may be serious or life-threatening. People with two copies of the ApoE ε4 gene face greater risk.
What families can do with preserved writing
A note can hold emotional value even when it proves nothing medically. Families may preserve the original, make a copy, record when it was found, and document what they reliably know about its author and timing.
Avoid labeling a note as someone's "last message" unless the family can establish that fact. If writing or language changes are new or worsening, use the NIA symptoms and diagnosis resource and bring dated examples to a clinical evaluation rather than trying to diagnose the cause from the writing alone.
